National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN Enzalutamide Research Grant Opportunity – Submit by July 28, 2014
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Updated Guidelines for Non-Small Cell Lung Cancer

The NCCN Clinical Practice Guidelines in Oncology™ for Non-Small Cell Lung Cancer have been updated and published on NCCN.org as Version.1.2010.

The updated NCCN Guidelines now include a description of maintenance therapy for patients with advanced or metastatic disease. This new section helps distinguish between recommended therapies for continuation maintenance versus switch maintenance.

Erlotinib has been added as a first-line treatment option for EGFR mutation positive patients with advanced or metastatic disease with a category 2A designation. Bevacizumab and cetuximab have been added as treatment options for continuation maintenance with a category 1 designation. Pemetrexed and erlotinib have been added as treatment options for switch maintenance with a category 2B designation and docetaxel has been added as a treatment option for switch maintenance with a category 3 designation.